Advance in Treatment of Chronic Lymphocytic Leukemia
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 58
Special Issue Editor
Special Issue Information
Dear Colleagues,
In the last decade we have seen a paradigm shift in the treatment of Chronic Lymphocytic leukemia. While the old standards of care of purine-analogue-based chemoimmunotherapy produced durable and, on occasion, lifelong disease control, the management of relapsed disease and high-risk patients with p53 abnormalities remained disappointing. The advent of targeted treatment of the B cell receptor and BCL-2 has revolutionized the efficacy and tolerability of treatment in this frequently older patient cohort with comorbidities and largely leveled the playing field in those with high-risk disease and consequently has replaced chemoimmunotherapy in front line and relapsed disease. We can also hopefully look forward to the next advances in treatment such as Bi-specific antibody treatments for the yet challenging patient group Richter’s transformation and third-generation BTK inhibitors for ‘double refractory’ CLL.
Dr. Patrick D. Thornton
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CLL
- Richter’s transformation
- BTK inhibitors
- BCL2
- Bi-specific antibodies
- CAR-T cell
